- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04494308
Evaluation of Eosinophil Phenotype in COPD Patients (V-FEO)
Pilot Study for Evaluation of Eosinophils Phenotype and Activation Status in COPD Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In about 30% of COPD patients there is an increased number of circulating eosinophils. On their membrane, eosinophils express several molecules, also related to their physiology, namely major histocompatibility complex (MHC) class II, needed for antigen presentation; CCR3, receptor for a variety of chemokines, including eotaxin (CCL11), eotaxin-3 (CCL26), monocyte chemotactict protein (MCP)-3 (CCL7), MCP-4 (CCL13), and RANTES (CCL5); cluster of differentiation (CD)125, which binds IL-5 and stimulates eosinophils proliferation; CD63, a marker that is upregulated after eosinophils degranulation; and CD294 (CRTH2) which is the prostaglandin D2 receptor, and is associated to allergy and inflammation . The hypothesis for the present trial is that different clinical phenotypes of COPD patients could be associated to different activation statuses of eosinophils, that can be evaluated analyzing by flow cytometry the membrane expression of the above mentioned molecules. In particular, the investigators hypothesize that membrane molecules may be modulated in different stages of the diseases, and may change after medical and rehabilitative therapies.
The investigators will analyze phenotype of eosinophils from blood samples of patients with COPD, admitted to the hospital after an episode of exacerbation, or for routine controls. In this way, the association between a particular pattern of molecules expressed on eosinophils membrane and the severity of COPD will be defined. Moreover, for hospitalized patients, eosinophils phenotype also on discharge day will be analyzed. In this way the effect of therapies on eosinophils activation will be assessed. Clinical status of patients will be assessed by standard tests such as St George Respiratory Questionnaire (SGRQ), BODE index, COPD Assessment Test (CAT), Six min. Walking Test (6'WT), Pulmonary Function Tests (PFT).
Eosinophils phenotype and in vitro cytokines production will be analyzed by multicolor flow cytometry. To minimize the effect of manipulation, staining of membrane molecules will be performed on whole blood samples, followed by lysis of erythrocytes. The following molecules will be analyzed: CD45, CD16, CD15, CD63, CCR3, CD125, CD294, Siglec-8. After in vitro stimulation with lipopolysaccharide (LPS) or CCL11, the production of interleukine (IL)-4, TGFbeta and IL-2 will be analyzed.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Vittorio Cardaci, MD
- Phone Number: +39 0666052336
- Email: vittorio.cardaci@sanraffaele.it
Study Contact Backup
- Name: Laura Vitiello, PhD
- Phone Number: +39 0652253440
- Email: laura.vitiello@sanraffaele.it
Study Locations
-
-
RM
-
Roma, RM, Italy, 00166
- Recruiting
- IRCCS San Raffaele Pisana
-
Contact:
- Vittorio Cardaci, MD
- Phone Number: +39 0666052336
- Email: vittorio.cardaci@sanraffaele.it
-
Contact:
- laura Vitiello, PhD
- Phone Number: +39 06 52253440
- Email: laura.vitiello@sanraffaele.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- COPD
- percentage of eosinophils >0%
- episode of exacerbation in the previous 10 days (for exacerbated cohort)
- no exacerbation in the previous 3 months (for stable cohort)
Exclusion Criteria:
- percentage of eosinophils =0%
- history of allergic diseases
- patients that are currently enrolled in other clinical trials involving new drugs or treatments
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
exacerbated
COPD patients admitted to the hospital for an exacerbation occurred within the past 10 days.
|
flow cytometric analysis of eosinophils membrane molecules
|
stable
COPD stable patients with no exacerbations in the past 3 months
|
flow cytometric analysis of eosinophils membrane molecules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Association of eosinophils phenotype with clinical status in COPD patients
Time Frame: one year
|
We expect to identify different patterns of expression of molecules on eosinophils membrane that are associated with different clinical phenotypes of COPD patients.
We will also associate eosinophils phenotype to the response to medical and rehabilitation therapy.
The definition of these patterns will provide a diagnostic tool to rapidly identify patients that will benefit from a specific therapy
|
one year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laura Vitiello, PhD, IRCCS San Raffaele Pisana, Roma
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RP 06/18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD
-
University Medical Center GroningenCompleted
-
Istituto Nazionale di Ricovero e Cura per AnzianiRecruiting
-
Bio-Sensing Solutions S.L. (DyCare)Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Centre...Recruiting
-
Sir Run Run Shaw HospitalRecruiting
-
University Hospital, BrestRecruiting
-
The First Affiliated Hospital of Guangzhou Medical...Recruiting
-
Association des Réseaux BronchioliteLaboratoire Système et Matériaux pour la Mécatronique (SYMME)Recruiting
-
Baylor Research InstituteNot yet recruiting
-
Polytechnic Institute of PortoNippon Gases PortugalRecruiting
Clinical Trials on biomarker identification
-
Maastricht UniversityUniversitaire Ziekenhuizen KU Leuven; University Medical Center Groningen; Maastricht... and other collaboratorsRecruitingDiagnoses Disease | Intestinal Disease | Acute Mesenteric IschemiaBelgium, Netherlands
-
IgenomixCompleted
-
EDUARDO ALBENIZInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Fundació... and other collaboratorsRecruitingGastric Cancer | Gastric Neoplasms | Gastric LesionSpain
-
University Hospital, Basel, SwitzerlandActive, not recruitingBloodstream InfectionsSwitzerland
-
US Department of Veterans AffairsCompletedHearing Loss, Sensorineural
-
University Hospital, Basel, SwitzerlandCompletedUrinary Tract Infection (Diagnosis)Switzerland
-
Aga Khan University Hospital, PakistanCompleted
-
University Hospital, MontpellierUnknownBalanced Chromosomal TranslocationFrance
-
Indonesia UniversityCompletedVascular Access ComplicationIndonesia